U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number.

Substitute for form 1449/PTO		C	Complete if Known		
INFORMATION DISCLOSURE			Application Number	10/790,943	
, i	STATEMENT BY	APPLICANT	Filing Date	9/3/2002	
	Data Submittad: I	May 20, 2000	First Named Inventor	William Robert Wilson	
Date Submitted: May 20, 2009			Art Unit	1614	
	(use as many sheet	's as necessary)	Examiner Name	James D. Anderson	
Sheet	1	of 1	Attorney Docket Number	093397-0501	

U.S. PATENT DOCUMENTS					
Examin	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
er Initials*	No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T€
	F25	WO 2009/053681	04-30-2009	Antisoma Research Limited		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	D72	Ghaemmaghami, et al., "New Agents in the Treatment of Small Cell Lung Cancer", Chest, 113(1) Suppl.: 86S-91S (1998).	
	D73	Horsman, et al., "Improving Conventional Cancer Therapy by Targeting Tumour Vasculature", British Journal of Cancer, 80(2) Suppl.: 90 (1999) Abstract	
	D74	Siemann, et al., "Potentiation of Chemotherapy by Vascular Targeting Agents", British Journal of Cancer, 80(2) Suppl.: 90 (1999) Abstract	

	,	
Examiner	Date	
Signature	Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.